Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

Paul S. Aisen1, Jeffrey Cummings2, and Lon S. Schneider3

1University of California, San Diego, California 92093
2Cleveland Clinic, Cleveland, Ohio 44195
3University of Southern California, Los Angeles, California 90007

Correspondence: paisen@ucsd.edu

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-D-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

REGULATORY LANDSCAPE AND CLINICAL TRIALS

North American and European Union regulatory criteria for marketing approval of putative symptomatic and disease-modifying therapeutic agents for Alzheimer disease (AD) are based on a demonstration of efficacy supported by improvements compared to placebo treatment on cognitive function, activities of daily living (ADL), and often evidence of overall clinical improvement or less overall decline, accompanied by adequate evidence of safety (Schneider 2008b). In practice this has led to rather standardized protocols by sponsors of experimental drugs. For example, mild to moderate AD is indexed by a Mini-Mental State Examination (MMSE) score of 10–26 and standardized outcomes including the Alzheimer’s Disease Assessment Scale—Cognitive Portion (ADAS-cog), the Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale, or the Disability Assessment for Dementia (DAD). A clinician’s global assessment (known as a Clinician Interview Based Impression of Change with caregiver input [CIBIC+] or ADCS Clinical Global Impression of Change [CGIC]) or the Clinical Dementia Rating (CDR), an interview-based overall dementia severity assessment, are the conventional outcomes measures. The trials are commonly 6–18 months in duration: 6 months for symptomatic and 12–18 months for disease-modifying trials. There is a current trend to include more mild patients with AD, operationalized as MMSE greater than 20, amnestic mild cognitive impairment (MCI), or MCI due to AD, prodromal or early AD
(supported by a positive cerebrospinal fluid [CSF] or imaging biomarker) (Schneider 2008b; Albert et al. 2011).

Five cholinesterase inhibitors, memantine, the Ginkgo biloba extract EGB 761, and cerebrolysin have some level of marketing approval for the treatment of AD in the Western hemisphere, Europe, Australia/New Zealand, Japan, and many Asian countries. One antipsychotic, risperidone, is specifically approved in several countries, e.g., UK, Spain, and Canada for the treatment of agitation, psychosis, or the behavioral and psychological symptoms of dementia (BPSD) occurring in AD.

Considering Mechanisms of Action

Demonstration of a mechanism, pharmacodynamic effect, or target engagement either in preclinical in vitro or in animal models, or in humans does not establish the relevance of the mechanism to the effect the drug might have on clinical manifestations. Many agents, including various antioxidant and so-called antiaging cocktails, are marketed based on the chemical properties of ingredients rather than randomized controlled trials of safety and efficacy. Such products may not have established safety, and certainly have no evidence of efficacy. Moreover, most drug products have multiple actions. Thus, with the few exceptions of drugs and antibodies that clearly engage only one target, characterizing a particular drug as having a certain mechanism of action may be misleading; yet this is often done as a matter of convenience or for categorization.

ACETYLCHOLINESTERASE INHIBITORS

Acetylcholinesterase inhibitors (AChE-Is) are the first class of agents specifically approved by the US Food and Drug Administration (FDA) for the treatment of AD (Fig. 1). Tacrine (Cognex) was approved in 1993 followed by approval of donepezil (Aricept) in 1996, rivastigmine (Exelon) in 2000, and galantamine (Reminyl, Razadyne) in 2001. Memantine (Namenda)—an NMDA receptor antagonist—approval followed in 2004 (Fig. 1). Tacrine had a short half-life requiring administration every 4 hours and had substantial associated hepatotoxicity, requiring frequent monitoring of liver enzymes. These limitations were not present with later AChE-Is. Tacrine is rarely used, is no longer available in many countries, and will not be discussed here.

All AChE-Is share the characteristic of inhibiting acetylcholinesterase and each of these agents has additional distinctive pharmacologic aspects. AChE-Is are thought to bind acetylcholinesterase in the synaptic cleft so that acetylcholine released from the presynaptic cholinergic terminal has an increased residence time within the synapse and is more likely to interact with the postsynaptic cholinergic receptor. The enhanced postsynaptic activity renders more normal the function of the cholinergic system.

Donepezil is a selective AChE-I, rivastigmine is a mixed acetylcholinesterase and butyrylcholinesterase inhibitor, and galantamine is described as having an allosteric nicotinic modulating effect as well as being an AChE-I. The clinical consequences of the differential pharmacology of the AChE-Is, if any, are unknown.

For purposes of drug development, patients were identified for AChE-I clinical trials as having mild to moderate AD by requiring a MMSE (Folstein et al. 1975) score between ten and 26 in most trials. All AChE-Is are approved for treatment of mild to moderate AD. In the clinical development of donepezil, trials of patients with moderate to severe AD were conducted and established efficacy of this agent in patients with MMSE scores of 0–15. Donepezil is approved for mild, moderate, and severe AD.

To meet the criteria for approval by the FDA as a treatment for AD, an agent must be shown in two well-conducted trials to be statistically significantly superior to placebo on a test of cognition (regarded as the central feature of AD) and a global scale or an assessment of ADL (Schneider 2008) The usual measure of cognition in mild to moderate AD is the ADAS-Cog (Rosen et al. 1984). In patients with moderate to severe AD the cognitive measure most
commonly used is the Severe Impairment Battery (SIB) (Schmitt et al. 1997). The global outcome used in most AChE-I trials is the CIBIC+ (Schneider et al. 1997). ADL scales used in AChE-I trials include the ADCS ADL scale (Galasko et al. 1997) or the DAD (Gelinas et al. 1999). Changes in behavior are commonly measured as secondary outcomes in AChE-I clinical trials, and the most commonly used instrument is the Neuropsychiatric Inventory (NPI) (Cummings et al. 1994). Pharmacoeconomic data are collected in some trials using the Resource Utilization in Dementia (RUD) scale (Wimo and Winblad 2003). Most clinical trials of AChE-Is have been 6 months in duration; some have been as short as 3 months and some as long as 2 years (AD2000 Collaborative Group 2004).

The responses to treatment with different AChE-Is have overlapping confidence intervals (CI), and no individual cholinesterase inhibitor has been shown to be superior to others in terms of efficacy. The mean response on the ADAS-cog is approximately 2.0 points with CI of 1.5–2.5 points (Birks 2006). The response on the CIBIC+ is usually in the range of 1.9 (CI 1.3–3.0) on a scale in which 4 represents no change, 3, 2 and 1 represent mild, moderate and marked improvement, and 5, 6, and 7 represent mild, moderate, and marked worsening (Whitehead et al. 2004). A two-point (CI 0.5–2.5) drug–placebo difference is common at trial conclusion on the ADCS ADL and a two-point (CI 0.5–4.0) drug–placebo difference on the NPI total score is common at trial conclusion. Approximately 25% of patients have a measurable improvement on the ADAS-Cog compared to 15% of patients on placebo. In addition to the drug–placebo difference in improvement, AChE-Is produce a delay in decline that affects as many as 80% of patients participating in a clinical trial (Geldmacher et al. 2006). Improvement on the ADAS-Cog is taken as an indication of improvement in the core clinical features of AD, whereas a drug–placebo difference in CIBIC+ or an ADL scale is accepted as a measure of clinically meaningful improvement. As noted, most clinical trials of AChE-Is are 6 months in duration and establish benefit for 6 months of therapy; some 1-year trials (Winblad et al. 2001) or 2-year trials (AD2000 Collaborative Group 2004) have been conducted and continued to show a drug–placebo difference at study conclusion. These observations support the long-term use of AChE-Is in the treatment of AD.

AD dementia is preceded by a period of cognitive impairment in which patients show decline in episodic memory and other cognitive abilities, but the changes are not sufficiently severe to reach the criteria for dementia. This clinical syndrome has been called mild...
cognitive impairment (MCI) (Petersen et al. 2001). Clinical trials of AChE-Is for the treatment of cognitive deficits of MCI have been uniformly negative (Jelic et al. 2006). It is now recognized that MCI is an etiologically heterogeneous state with only approximately 60–70% of patients having underlying AD (Jicha et al. 2006). The lack of response to AChE-Is in MCI may reflect the absence of an AD-type pathophysiology in a substantial number of patients included in the trial. In the ADCS MCI study, there was a drug-placebo benefit in favor of donepezil in MCI patients who were apolipoprotein E4 carriers, a group likely to have a high underlying rate of AD pathophysiology (Petersen et al. 2001). This suggests that prodromal AD may respond to treatment by AChE-Is. However, many of the patients enrolled in MCI trials could also have fulfilled criteria for AD.

Gastrointestinal side effects are common in patients placed on AChE-Is. Anorexia, nausea, vomiting, diarrhea, and weight loss may occur and should be monitored in patients treated with these agents. In addition, cholinergic influences may slow heart rate and bradycardia is a contraindication to use of AChE-Is. Occasional patients have experienced changes in urinary function. Muscle cramps have been reported with donepezil and abnormalities in dreaming also have been reported with donepezil.

In addition to the use of AChE-Is in AD, rivastigmine has been approved by the FDA for treatment of mild to moderate Parkinson’s disease dementia (Emre et al. 2004). AChE-Is have also been assessed in clinical trials of vascular dementia (Black et al. 2003; Kavirajan and Schneider 2007), mixed AD and cerebrovascular disease (Erkinjuntti et al. 2002), and dementia with Lewy bodies (McKeith et al. 2000). None of these indications has been approved by the FDA and use of AChE-Is in these settings is off label.

Donepezil has a half-life of 70 hours and is administered once daily (Table 1). It is 96% protein bound with 100% bioavailability; it is metabolized by 2D6 and 3A4 cytochrome P450 enzymes. Treatment is begun with 5 mg/day and, if the patient shows no intolerance, the dose is advanced to 10 mg/day usually after 1 month. A 23 mg once-daily dose has recently been approved for use in patients with moderate to severe AD (Okamura et al. 2008). Acetylcholinesterase positron emission tomography (PET) studies suggest that the 10 mg dose produces an approximately 60% inhibition of central acetylcholinesterase (Okamura et al. 2008). Rivastigmine has a peripheral half-life of 1.5 hours and a central half-life of 8 hours. The capsules are given twice daily and, when administered as the patch formulation, the patch is replaced once daily. Rivastigmine is not metabolized through the cytochrome P450 system; it is 40% protein bound and has 40% bioavailability. Rivastigmine is initiated in an oral dose of 1.5 mg orally twice daily and, as tolerance is determined, advanced to 3 mg, 4.5 mg, and 6 mg twice daily for a total target dose of 12 mg/day. Titration is typically at 1-month intervals and is determined by patient tolerance for the agent. The transdermal patch formulation of rivastigmine is initiated at a patch strength of 4.6 mg and advanced to 9.5 mg after 1 month if no intolerance is observed. Galantamine has a half-life of 7 hours and is given twice daily, unless the extended release formulation is used and administered once daily. Galantamine is initiated at a dose of 4 mg twice daily (8 mg/day in a single dose for the extended release formulation) and advanced to 16 and 24 mg/day at 1-month intervals. Galantamine is metabolized by the cytochrome P450 enzymes 2D6 and 3A4. It is 18% protein and has 90% bioavailability.

There are conflicting data as to whether AChE-Is have any disease-modifying properties with respect to AD. They affect disease course by improving symptoms and delaying decline as described above. Basic science observations suggest that enhancement of cholinergic function may reduce the generation of β-amyloid protein (Kimura et al. 2005). Some imaging studies have suggested less brain atrophy over time in patients treated with AChE-Is (Krishnan et al. 2003). In addition, some long-term observations suggest less decline in patients treated with AChE-Is or combination therapy of AChE-Is with memantine compared to
patients not receiving therapy with these agents (Lopez et al. 2009; Rountree et al. 2009). Other clinical and imaging studies, however, suggest no disease-modifying benefit from treatment with AChE-Is (Jack et al. 2008; Schneider and Sano 2009). Disease-modifying effects, if present, must be small in magnitude.

Patients intolerant to one AChE-I may be able to tolerate an alternate cholinesterase inhibitor and the effort to keep patients on therapy should be made when intolerance occurs. Patients started on an oral medication might be switched to patch therapy or vice versa. Patients showing no efficacy in response to treatment with one cholinesterase inhibitor (uninterrupted continuing decline of cognition) may also be switched to another. Any benefit from switching in this circumstance however is not established.

Continuing benefit from use of AChE-Is has been shown in trials lasting up to 2 years, among patients followed over that length of time (AD2000 Collaborative Group 2004). In addition, patients with severe AD—not previously treated with AChE-Is—respond to treatment with AChE-Is, and donepezil is approved for treatment in this advanced phase of the disease. These observations suggest that long-term treatment with AChE-Is may continue to provide benefit. When AChE-Is are discontinued because the patient or the clinician believe that no further benefit is possible, patients should be observed for cognitive decline, loss of ADL, or emergent behavioral disturbances (Holmes et al. 2004). If adverse cognitive, functional, or behavioral changes occur soon after discontinuation then physicians and patients should consider whether the patient had been

Table 1. Characteristics of cholinesterase inhibitors

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Donepezil</th>
<th>Rivastigmine</th>
<th>Galantamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade name</td>
<td>Aricept (Aricet in some countries)</td>
<td>Exelon</td>
<td>Razadyne and Razadyne-ER</td>
</tr>
<tr>
<td>Indications</td>
<td>Mild to moderate and severe AD</td>
<td>Mild to moderate AD</td>
<td>Mild to moderate AD</td>
</tr>
<tr>
<td>Half-life</td>
<td>70 hours</td>
<td>1.5 hours (brain half-life is 8 hours)</td>
<td>7 hours</td>
</tr>
<tr>
<td>Administration schedule</td>
<td>q.d.</td>
<td>b.i.d. for capsules; q.d. for the patch</td>
<td>b.i.d. for the non-ER form: q.d. for the ER form</td>
</tr>
<tr>
<td>Metabolism by hepatic CYP enzymes</td>
<td>2D6, 3A4</td>
<td>No</td>
<td>2D6, 3A4</td>
</tr>
<tr>
<td>Protein binding</td>
<td>96%</td>
<td>40%</td>
<td>18%</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>100%</td>
<td>40%</td>
<td>90%</td>
</tr>
<tr>
<td>Time to peak serum level</td>
<td>3–4 hours</td>
<td>1 hour</td>
<td>1 hour (2.5 hours with food); 4.5 hours for ER form</td>
</tr>
<tr>
<td>Absorption delayed by food</td>
<td>No</td>
<td>No</td>
<td>Yes (1 hour to 2.5 hours)</td>
</tr>
<tr>
<td>Titration</td>
<td>Begin with 5 mg and advance to 10 mg after 1 month</td>
<td>Oral form: 1.5 mg b.i.d. for 4 weeks; 3 mg b.i.d. for 4 weeks; 4.5 mg b.i.d. for 4 weeks; advance to 6 mg b.i.d. if tolerated</td>
<td>Non–ER form: begin 4 mg b.i.d.; advance to 8 mg b.i.d. after 1 month and to 12 mg b.i.d. after 1 month</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patch form: begin the 5 cm² patch for 1 month then advance to 10 cm² patch</td>
<td>ER form: begin at 8 mg q.d.; advance after 1 month to 16 mg DQ and after 1 month to 24 mg q.d.</td>
</tr>
</tbody>
</table>

Tacrine (Cognex) is now rarely used because of associated liver enzyme elevations and is not included in this chart.

Cite this article as Cold Spring Harb Perspect Med 2012;2:a006395
benefiting from treatment and whether to reinitiate medications at the starting doses.

MEMANTINE

Memantine was used in Germany for the treatment of Parkinson’s disease prior to its approval in the USA and globally for treatment of AD. A key 12-week clinical trial of memantine for patients with dementia, mainly AD, residing in nursing homes was published in 1999 (Winblad and Poritis 1999) followed by publication of a monotherapy trial in 2000 (Reisberg et al. 2003a) and of a donepezil add-on trial in 2004 (Tariot et al. 2004). Memantine was approved by the FDA in the USA in 2004 for treatment of moderate to severe AD, meaning patients with MMSE scores less than 15. Memantine is an NMDA receptor antagonist that replaces potassium in the NMDA receptor channel to reduce entry of calcium into neurons and avoid calcium-stimulated apoptotic cell death cascades. It is uncertain if the neuroprotective activities observed consistently in in vitro studies account for the symptomatic benefit observed in clinical trials. In vitro experimental studies suggest reduced Aβ plaque deposition and reduced tau hyperphosphorylation following treatment with memantine (Martinez-Coria et al. 2010). Physiological studies establish a beneficial effect for long-term potentiation (LTP), the physiological correlate of memory (Frankiewicz and Parsons 1999). This latter observation provides a potential explanation for the symptomatic benefit observed with treatment with memantine.

Clinical trials of memantine have been very similar in design to those conducted with AChE-Is, but have involved patients with moderate to severe AD, rather than mild to moderate AD. Trials have typically been 6 months in duration with the SIB, CIBIC+, or ADCS-ADL as primary outcomes and ADL or behavior as secondary outcomes. The magnitude of benefit from treatment with memantine is similar to the magnitude observed for AChE-Is. Two of three moderate to severe AD trials with memantine showed statistical significance on their primary outcomes (Reisberg et al. 2003b; van Dyck et al. 2007), including an add-on trial, in which patients on long-term treatment with donepezil, randomized to receive either placebo or add-on memantine, showed that add-on therapy with memantine produced a statistically significant benefit compared to add-on therapy with placebo (Tariot et al. 2004).

Several clinical trials have been conducted with memantine patients with mild to moderate AD. One of these trials showed benefit on cognition, global assessment, and behavior (Peskind et al. 2006); two trials did not show significant drug-placebo differences (Bakchine and Loft 2008; Porsteinsson et al. 2008). Memantine is not approved by the FDA for patients with mild AD. European regulatory authorities extended the range of approval for use of memantine to patients with MMSE scores of 19 and below.

Memantine has a half-life of 60–80 hours, is 50% protein bound, is not metabolized by the cytochrome P450 hepatic enzymes, and its absorption is not delayed by food (Table 2). Memantine is subject to renal excretion and the dose should be decreased by 50% in AD patients with renal failure. Memantine is initiated at a dose of 5 mg per day for 1 week, it is then advanced to 5 mg twice daily for 1 week; the next dose is 10 mg in the morning and 5 mg in the evening for 1 week; and the final dose is 10 mg twice daily. This is the continuing permanent dose for patients who do not have evidence of intolerance. Adverse events reported with memantine therapy include headache, dizziness, and somnolence. There have been reports of confusion during the titration period and occasional reports of hallucinations.

Memantine is approved for moderate to severe AD and may be given either alone or in conjunction with an AChE-I. No adverse drug interactions have been reported with patients receiving AChE-Is plus memantine, and the drugs are safe when used together. Although some long-term open-label observations suggest that combination therapy with an AChE-I and memantine may ameliorate the course of AD (Lopez et al. 2009; Rountree et al. 2009), other studies suggest otherwise (Schneider et al. 2011). Observations in the course of...
double-blind placebo-controlled trials suggested that patients on therapy decline at equal rates when compared to patients not receiving therapy (Schneider and Sano 2009).

Patients are usually treated with memantine or a combination of an ACHE-I plus memantine until late in the course of AD. Pharmacotherapy may be continued until the patients succumb or until their physicians and family conclude that the quality of life of the patient is sufficiently compromised that pharmacotherapy is futile.

### Use of Psychotropic Agents to Treat Behavioral Disturbances in AD

Behavioral disturbances are common in AD, including depression, agitation, irritability, aberrant motor behaviors, and psychosis (Cummings 2003). There are no agents approved by the FDA specifically for treatment of behavioral disturbances in AD. Antipsychotics—both conventional and atypical—are associated with increased mortality and some antipsychotics are associated with increased risk for cerebrovascular accidents or stroke when administered to elderly patients with AD. The risk of death is increased from $\sim 2.6\%$ to $\sim 4.5\%$ during an average of 10 weeks of therapy. Long-term observations suggest that continuing therapy is associated with a continuing increased risk for mortality (Kales et al. 2007; Ballard et al. 2009). Several 1–12 week long clinical trials suggest that risperidone and possibly other atypical antipsychotic agents in low doses are efficacious in reducing psychosis and agitation in mainly nursing home patients with AD (Ballard and Waite 2006; Schneider et al. 2006). Given the evidence of benefit and harm for the use of antipsychotics in AD, the clinician must exercise caution when prescribing these agents. Strategies for use of antipsychotics in patients with AD involve avoiding their use in patients with cardiovascular or pulmonary disease (the two most common causes of death in mortality studies), using these agents only in patients for whom nonpharmacologic interventions have failed and the behaviors are extreme, employing treatment for only the period required and attempting to eliminate the agents as soon as possible, and informing the patient and caregiver of the risks involved.

Clinical trials have been largely negative in showing benefit for treatment of depression in AD with antidepressant medications (Lyketsos et al. 2000; Olin et al. 2002; Rosenberg et al. 2010; Weintraub et al. 2010). There is no consistent evidence base for the use of antidepressants in AD. Individual practitioners may use practice-based evidence to guide their therapeutic decisions. Several recent trials suggest that use of valproate to treat agitation has no superiority over placebo and is associated with substantial toxicity (Tariot et al. 2005; Herrmann et al. 2007). Early trials suggested the benefit of carbamazepine as a treatment for agitation (Tariot et al. 1998). Anxiolytics and

### Table 2. Characteristics of memantine

<table>
<thead>
<tr>
<th>Trade name</th>
<th>Namenda (Ebixa or Axura in some countries)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
<td>Moderate to severe AD (USA) up to MMSE scores of 20 in Europe and Asia</td>
</tr>
<tr>
<td>Half-life</td>
<td>60–80 hours</td>
</tr>
<tr>
<td>Protein binding</td>
<td>50%</td>
</tr>
<tr>
<td>Metabolism by hepatic CYP enzymes</td>
<td>No</td>
</tr>
<tr>
<td>Absorption delayed by food</td>
<td>No</td>
</tr>
<tr>
<td>Time to peak serum level</td>
<td>3–7 hours</td>
</tr>
<tr>
<td>Adjustment in hepatic or renal disease</td>
<td>Decrease dose by 50% in patients with renal failure</td>
</tr>
<tr>
<td>Titration</td>
<td>5 q.d. for 1 week; 5 b.i.d. for 1 week; 10 mg in a.m. and 5 mg in p.m. for 1 week; 10 mg b.i.d. thereafter</td>
</tr>
</tbody>
</table>
hypnotics are generally to be avoided in patients with AD as they may increase confusion. Short-term use of benzodiazepines such as lorazepam or clonazepam may be useful in patients with episodes of agitation.

There is an urgent need for effective, safe, psychotropic agents for treatment of behavioral disturbances in AD and other dementing disorders.

OTHER TREATMENTS MARKETED FOR AD IN SOME COUNTRIES

The following three substances are approved for use or widely used in some individual countries for cognitive impairment syndromes but are not FDA or EMA approved.

Ginkgo Biloba

Ginkgo biloba leaves and extracts are widely used in over-the-counter preparations marketed in the USA as food supplements or nutraceuticals and, as such, explicit health claims are not listed in their labeling (Schneider 2008a). In several countries G. biloba is advocated for the treatment of a broad range of medical conditions including, as examples, tinnitus and dizziness. The extract that is approved for use in some countries is Ginkgo biloba extract EGb 761 (Ipsen Pharma, and Schwabe Pharmaceuticals), standardized to contain two major constituents: 22–27% flavonoids and 5–7% terpene lactones (ginkgolides and bilobalide).

The flavonoids are active as antioxidants and appear neuroprotective. Ginkgolide B is a potent antagonist of the platelet-activating factor receptor. Ginkgolides A and J variously inhibit hippocampal neuron dysfunction and neuronal cell death caused by amyloid-β protein-42 (Aβ42). Ginkgolides A and J decrease Aβ42-induced pathological behaviors, enhance neurogenesis in animal models of AD, and inhibit Aβ aggregation, providing considerable rationale for G. biloba extracts as potential treatments for AD.

Trials in older and younger adults who do not have cognitive impairment show mixed results at best (Schneider 2008a). One meta-analysis of eight trials did not find evidence for cognitive benefits with G. biloba in noncognitively impaired participants younger than 60 years treated for up to 13 weeks. Two placebo-controlled trials reported contradictory effects in noncognitively impaired older adults, and the magnitude of the cognitive effects were small in the positive trial.

A systematic review that included 35 clinical trials and 4247 participants reported inconsistent evidence that G. biloba had clinically significant benefits for dementia or cognitive impairment (Birks and Grimley Evans 2009). One 6-month trial in mild to moderate AD sponsored by Schwabe Pharmaceuticals, conducted with the hope of gaining US FDA marketing approval, failed to demonstrate efficacy (Schneider et al. 2005), as did another 6-month trial performed at British primary care sites with 120 mg/day doses of EGb 761 (McCarney et al. 2008).

Perhaps because of its popularity and perceived safety there have been three prevention trials undertaken using EGb 761 at 240 mg daily doses. A trial involving 118 participants without MCI or dementia, all older than 85 years, randomized to receive G. biloba extract or placebo and followed up for 42 months, showed a nonsignificant effect for G. biloba to delay progression to MCI (Dodge et al. 2008). Of potential concern, however, was that more ischemic strokes and transient ischemic episodes occurred in the G. biloba group. The GEM trial randomized 3069 persons to G. biloba extract or placebo who had no cognitive impairment or MCI for a median duration of more than 6 years and found no clinical effects for the extract on cognition or time to dementia (DeKosky et al. 2008). A second prevention trial, GuidAge, conducted in France and involving 2854 participants with memory complaints or MCI, randomized to G. biloba or placebo and followed for more than 5 years, also failed to find effects for ginkgo on the primary outcome of time to onset of AD or other dementia (Ipsen press release, 22 June 2010). Thus, there is very little evidence for the efficacy of G. biloba either for improving symptoms or preventing AD.
Cerebrolysin

Cerebrolysin is a somewhat controversial approach to neurotrophic therapy for AD. This product is a parenterally administered digested peptide preparation derived from pig brain. In vitro studies suggest that this peptide mixture has neuroprotective effects. There is some evidence of brain penetration with peripheral administration. There have been a number of clinical studies of Cerebrolysin infusion therapy in AD, with some results suggesting symptomatic benefit (Okamura et al. 2008). As a result, it has been widely used in many countries. Skepticism arises from the poorly defined composition and mechanisms and inconsistencies in clinical findings, but some have called for more definitive trials.

Huperzine A

Huperzine A is a plant extract with potent, selective AchE1 inhibition used in China for the treatment of dementia. Preclinical studies suggest possible neuroprotective mechanisms. A recent Phase II trial in the USA failed to demonstrate efficacy of the usual dose used in China, 200 mcg twice daily, but did provide some evidence of cognitive enhancement at twice this dose (Rafii et al. 2011).

DIETARY SUPPLEMENTS, VITAMINS, NUTRICEUTICALS, MEDICAL FOODS

A dietary supplement is defined by US law as a product (other than tobacco) that is intended to supplement the diet; contains one or more dietary ingredients (including vitamins, minerals, herbs or other botanicals, amino acids, and other substances) or their constituents; is intended to be taken by mouth; and is labeled on the front panel as being a dietary supplement (United States Dietary Supplement Health and Education Act of 1994 (http://www.fda.gov/opacom/laws/dshea.html#sec3).

The word nutraceutical has no official meaning, but was coined to imply nontraditional products with pharmaceutical effects. A dietary supplement promoter cannot make a health-disease treatment claim for the substance. Thus, for example, a supplement could be advertised as enhancing “brain power,” brain cells or concentration, but not as a treatment for AD or attention deficit disorder, as the latter are health claims.

Several dietary supplements and vitamins have been used in clinical trials for AD, cognitive impairment, or age associated memory impairment (AAMI; older individuals who have cognitive test scores below the norms for young adults) and have been indirectly promoted by various interest groups as treatments for AD. Formulations of these substances vary, with no regulatory standard except that products must contain the substance advertised.

Docosahexaenoic Acid

Docosahexaenoic acid (DHA) is the primary constituent of membranes in the central nervous system (CNS). DHA levels in brain decline with age, but can be restored with dietary supplementation. Adding DHA to the diet of transgenic mice with amyloid deposition in brain reduces amyloid accumulation and improves cognitive performance. There is thus a reasonable rationale for studying DHA supplementation as a therapeutic intervention for cognitive aging and AD.

One trial conducted by a manufacturer of DHA, Martek, in individuals with AAMI did not yield significant results. Post-hoc analyses suggest possible benefits in measures of episodic memory (Okamura et al. 2008).

An NIA-funded trial of DHA for mild to moderate AD was, however, negative (Quinn et al. 2010). Treatment with DHA for 18 months increased CSF levels (in the subset who underwent lumbar punctures), but did not alter the decline in cognitive and functional assessments.

B Vitamins

Elevated homocysteine in blood is considered a risk factor for cardiovascular disease, vascular dementia, and AD. Plasma concentrations increase when homocysteine’s metabolism to methionine or cysteine is impaired, which may
occur under a number of circumstances, including natural aging. Increased blood levels of homocysteine are associated with damage to vascular endothelial cells through lipid peroxidation and release of endothelium-derived relaxing factor, and may increase the risk of vascular thrombosis. More relevant to AD, homocysteine potentiates the neurotoxic effects of β-amyloid peptides in vitro. Homocysteine plasma levels can be reduced by as much as 30% using regimens of B vitamins (e.g., B12 1 mg/day, B6 25 mg/day, and folic acid 5 mg/day). A placebo-controlled clinical trial of these vitamins over 18 months confirmed that substantial reduction in homocysteine could be achieved but did not slow the rate of cognitive decline in AD compared to placebo (Aisen et al. 2008; Okamura et al. 2008). A study of a similar regimen in individuals with MCI showed reduction of whole brain atrophy with vitamin use for 2 years (Smith et al. 2010). A fixed combination of B6, B12, and folate known as Cerefolin is marketed as a medical food (see below) for treatment of metabolic abnormalities associated with AD.

Vitamin E

The antioxidant effects of vitamin E (DL-α-tocopherol) might have an impact on reducing clinical progression. In the prototypical antioxidant trial, vitamin E (1000 IU twice a day) and selegiline (5 mg twice a day), each given alone to moderately impaired patients with AD, delayed the time until patients required nursing home placement, died, or lost ADL (Sano et al. 1997).

Overall, the delayed time to these end points was approximately 7 months compared to placebo. There were no effects on cognition in this group of patients, who were more severely impaired than in many other studies. Adverse effects included falls and syncope in selegiline patients (9 and 10%, respectively), α-tocopherol patients (14 and 7%, respectively), and the combination (22 and 16%, respectively).

A multicenter trial in MCI patients reported no significant delay in conversion to AD or dementia in cognitive effects with α-tocopherol (or donepezil) over 3 years of treatment (Petersen et al. 2005). Taken together, considering the absence of cognitive efficacy and the potential risks for treatment, vitamin E cannot be recommended as treatment.

Homotaurine

Originally synthesized and manufactured as a drug in development for AD under the name tramiprosate (3-amino-1-propanesulfonic acid) and the trade name Alzhemed, the amino acid homotaurine is now sold in Canada as a nutraceutical under the brand name Vivimind. The rationale for this is that, although the product is synthesized, homotaurine is also a natural component of certain seaweeds.

The rationale for its development as a prescription drug for AD was as an Aβ aggregation inhibitor. After a Phase II safety study in which CSF Aβ was decreased (Aisen et al. 2006), two 18-month Phase III trials (one of which was stopped early) did not show efficacy. The company currently advances its use without a specific health claim as a food supplement.

MEDICAL FOODS

A medical food is “a food which is formulated to be consumed or administered enterally (or orally) under the supervision of a physician, and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation,” under the Orphan Drug Amendments of 1988 and the Nutrition Labeling and Education Act of 1990 (see 21 U.S.C. sec. 360ee(b)(3), 21 C.F.R. sec. 101.9(j)(8), and “Guidance for Industry: Frequently Asked Questions About Medical Foods” (May 2007), FDA website).

In addition, the contents of a medical food must fulfill the Generally Recognized as Safe (GRAS) designation for foods.

Axona (Ketasyn; AC-1202)

A mixture of medium-chain triglycerides, brand named Axona, was marketed in March 2009 as a medical food for AD. The rationale

P.S. Aisen et al.
is that AD or other cognitive impairment may be partly a consequence of impaired glucose metabolism (see below), and that this can be treated by using medium-chain triglycerides that are converted to ketones, raising ketone levels, which enhance mitochondrial electron transport that otherwise was impaired by the impaired glucose metabolism (Henderson et al. 2009). Separately, some studies show that a ketogenic diet reduces Aβ40 and 42 in transgenic mice.

In two 12-week placebo-controlled randomized trials for AD and AAMI there was no statistical evidence for cognitive or behavioral effects (Henderson et al. 2009). In the trial with 152 AD patients significant improvements on the ADAScog were noted at 6 weeks but not at 12 weeks, and post hoc the very few APOE4-negative patients in the trial seemed to improve at 12 weeks (Henderson et al. 2009). The 159-patient trial with AAMI patients was also not significant, showing two of the memory subscales to be significant in post hoc analyses.

Souvenaid

Another company, Danone, is developing and testing in clinical trials a brand name medical food, Souvenaid, that is comprised of a combination of food supplements, including uridine monophosphate, choline, omega-3 fatty acids (EPA, DHA), phospholipids, B vitamins, and antioxidants (Scheltens et al. 2010). The rationale is that this specific combination might synergistically enhance dendritic spine growth, synapse formation, neurotransmitter precursors, and neurotransmitter release, ultimately improving cognitive function. The company also claims the combination reduced amyloid production and toxicity in the preclinical models. Results of a 12-week, placebo-controlled trial in 225 patients with AD were nonsignificant on most of the outcomes (Scheltens et al. 2010). There are ongoing, longer, and larger trials in the USA and Europe.

Thus, there is no evidence for efficacy for these two medical foods and more studies are needed.

OTHER NEUROTRANSMITTER-BASED TREATMENTS

Cholinergic Agonists

A range of M1, muscarinic agonists with variable specificity for the M1 receptor subtype have been tested in 6-month symptomatic trials. Although some have shown distinct cognitive signals on standard clinical trials outcomes, they also produce considerable and troublesome cholinergic adverse effects such as gastrointestinal disturbances, diaphoresis, syncope, and hypersalivation. The M1 agonists also show salutary effects on Aβ in preclinical models. There have been no trials of lower doses over longer time periods to assess the potential for disease modification.

Neuronal Nicotinic Receptor Agonists

Neuronal nicotinic acetylcholine receptors (NNRs) are widespread throughout the central and peripheral nervous system. They mediate aspects of memory, attention, arousal, mood, anxiety, and sensory perception. NNR agonists can affect acetylcholine receptors through full and partial agonism or positive allosteric modulation. Receptor stimulation may increase release of several neurotransmitters implicated in CNS disorders including dopamine, serotonin, glycine, glutamate, and GABA. There may be a physiological inverted dose-response where low doses of NNR agonists enhance cognition and higher doses do not.

Two classes of NNRs may be involved in CNS disorders: (1) α7, and (2) α4/β2, and serve as targets. The α7 agonists predominate in areas more directly linked to memory and may also serve a neuroprotective function by reducing oxygen free radicals and nitric oxide. An α7 agonist in particular could be expected to be both symptomatic and have disease modifying properties as it enhances cognitive performance in behavioral models that capture domains of working memory, recognition memory, memory consolidation, and sensory gating deficit, increases the release of both presynaptic and postsynaptic calcium, and increases the release of Ach, glutamate, serotonin, and dopamine.
PDE Inhibition

A rational behind phosphodiesterase 4 (PDE4) inhibition is that it leads to CREB up-regulation, which should promote neurotrophin expression, and thus may have both cognition enhancing and neuroprotective effects. The molecules in development so far have not succeeded, having manifested significant cardiac and gastrointestinal adverse effects.

EHT0202 (etazolate HCl) shows both potential symptomatic and disease-modifying effects in AD, acting as a PDE-4 inhibitor and GABA-A receptor modulator, increasing $\alpha$-secretase activity and sAPP $\alpha$ secretion, thus lowering A$\beta$. PDE inhibitors involving a variety of PDE enzymes are being tested in early-phase AD trials (Okamura et al. 2008).

AMPA Receptor Modulation

More challenging, in terms of safety, is the work being done on neurotrophically high-impact AMPA modulators. Lilly’s high-impact LY451395 failed in an AD Phase II trial, but this trial used tiny doses (0.2 mg for 28 days, then 1.0 mg thereafter) which speaks to the low therapeutic index, probably related to seizure risk. Cortex believes they have achieved the necessary balance between trophic effect and seizure risk with CX-1837, but have not completed that molecule’s preclinical testing.

H3 Antagonists

The H3 receptor has the highest affinity for histamine among the four histamine receptors and is predominantly expressed in the cerebral cortex, hippocampus, and hypothalamus in which it functions as a presynaptic autoreceptor to regulate histamine release and cholinergic and monoaminergic neurotransmitter release. H3 blockade results in the release of neurotransmitters and is associated with enhanced cognitive function in preclinical models. Several H3 receptor agonists are in early stage clinical trials for treatment of the cognitive or motivational aspects of AD.

OTHER APPROACHES TO AD TREATMENT

There are many drug development programs pursuing strategies not directly related to amyloid, tau, or neurotransmission. As discussed above, the putative mechanisms may be impossible to specify and may be multiple; there is generally no way to connect drug activity in experimental symptoms specific to clinical results in the management of AD. Many such agents are listed in Table 3, and examples are discussed below.

DRUGS WITH METABOLIC ACTIONS

There is evidence that diabetes may increase the risk of AD, and a variety of animal and human studies support the concept that insulin resistance in brain may play a role in AD (Craft 2007). Increasing attention is being paid to the possible interrelationship between AD and diabetes as epidemiologic studies suggest that people with Type 2 diabetes mellitus are twice as likely to develop AD as nondiabetics. Insulin may prevent the soluble toxic form of A$\beta$ from damaging neurons. Insulin protection was enhanced by the presence of rosiglitazone. Intranasal or IV insulin has been shown to improve cognitive performance in small studies of individuals with AD. Additional studies of insulin therapy are planned.

PPAR$\gamma$-Agonists

The peroxisome proliferator activated receptor $\gamma$ (PPAR$\gamma$) is activated by a variety of fatty acids and fatty acid derivatives, and regulates adipocyte differentiation and function. PPAR$\gamma$-agonists such as rosiglitazone (Avandia) and pioglitazone (Actos) further mediate insulin actions and are marketed drugs for diabetes. They also may have actions relevant to AD, including anti-inflammatory effects. However, a study of a pioglitazone found mixed results, with no difference on most cognitive measures (Sato et al. 2009; Geldmacher et al. 2011). Six- and 12-month Phase III trials of rosiglitazone, a PPAR$\gamma$ agonist also targeting insulin resistance and related pathways failed to
### Table 3. Selected drug development programs

<table>
<thead>
<tr>
<th>Name</th>
<th>Sponsor</th>
<th>Proposed mechanism or therapeutic rationale</th>
<th>Target population</th>
<th>Supportive studies</th>
<th>Nonsupportive studies/issues</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin</td>
<td>NIA</td>
<td>Correction of insulin abnormalities that may contribute to pathology and synaptic dysfunction</td>
<td>MCI, AD</td>
<td>Small Phase II RCTs with some positive effects (Craft et al. 2011)</td>
<td></td>
<td>Additional Phase II trials planned</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>GSK</td>
<td>Anti-inflammatory effect; improve brain insulin resistance</td>
<td>AD</td>
<td>Exploratory Phase II analyses (Risner et al. 2006)</td>
<td>Phase III</td>
<td>Not actively pursued</td>
</tr>
<tr>
<td>Dimebon</td>
<td>Medivation/ Pfizer</td>
<td>Mitochondrial neuroprotectant</td>
<td>AD, HD</td>
<td>Phase II (Doody et al. 2008)</td>
<td>Phase III monotherapy</td>
<td>Phase III add-on study in progress</td>
</tr>
<tr>
<td>DHA</td>
<td>NIA, Martek</td>
<td>Restore membrane function</td>
<td>AD, AAMI</td>
<td>Epidemiology plus post-hoc analyses in cognitive aging trial</td>
<td>ADCS trial in AD</td>
<td>Additional studies in genetic subgroups and/or MCI are under discussion</td>
</tr>
<tr>
<td>Cerebrolysin</td>
<td>EBEWE</td>
<td>Neurotrophic activity</td>
<td>AD</td>
<td>Effect of some doses on cognition or global status in randomized trials</td>
<td>Inconsistent results</td>
<td>Marked in many countries</td>
</tr>
<tr>
<td>Statins</td>
<td>NIA, Pfizer</td>
<td>Alter cholesterol/amyloid pathways</td>
<td>Normal, AD</td>
<td>Epidemiology, small randomized study</td>
<td>ADCS, LEADe</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>Estrogen</td>
<td>NIA</td>
<td>Engage brain estrogen receptors</td>
<td>Normal, AD</td>
<td>Epidemiology, small randomized study</td>
<td>ADCS, WHI, Merck</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>NIA, Merck</td>
<td>Reduce harmful brain inflammation</td>
<td>AD, MCI</td>
<td>Epidemiology</td>
<td>ADCS, Merck</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>NIA, Pfizer</td>
<td>Reduce harmful brain inflammation</td>
<td>AD, MCI</td>
<td>Epidemiology</td>
<td>ADCS, Merck</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>B vitamins</td>
<td>NIA</td>
<td>Reduce homocysteine</td>
<td>AD</td>
<td>Epidemiology</td>
<td>ADCS, MK-677 trial</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>HGH, IGF-1</td>
<td>Merck, others</td>
<td>Normalize HGH-IGF-1 pathways</td>
<td>AD, aging</td>
<td>Epidemiology</td>
<td>ADCS, MK-677 trial</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>Lithium</td>
<td>NIA</td>
<td>Inhibit tau phosphorylation plus other neuroprotective mechanisms</td>
<td>AD, tauopathies</td>
<td>Preclinical data</td>
<td>Negative RCT</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>NIA</td>
<td>Inhibit tau phosphorylation plus other neuroprotective mechanisms</td>
<td>AD</td>
<td>Preclinical data</td>
<td>Negative RCT</td>
<td>Not actively pursued for AD</td>
</tr>
</tbody>
</table>

Continued
### Table 3. Continued

<table>
<thead>
<tr>
<th>Name</th>
<th>Sponsor</th>
<th>Proposed mechanism or therapeutic rationale</th>
<th>Target population</th>
<th>Supportive studies</th>
<th>Nonsupportive studies/issues</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resveratrol</td>
<td>NIA</td>
<td>SIRT-1</td>
<td>AD, normal aging</td>
<td>In vitro, animal studies</td>
<td>Limited brain penetration</td>
<td>RCT in AD beginning</td>
</tr>
<tr>
<td>Axona</td>
<td>Accera</td>
<td>Correct ketone body accumulation</td>
<td>AD</td>
<td>Post-hoc results</td>
<td>Negative RCT</td>
<td>Marketed as medical food</td>
</tr>
<tr>
<td>Souvenaid</td>
<td></td>
<td>Combination of vitamins to improve brain cell function</td>
<td>AD</td>
<td>Post-hoc results</td>
<td>Negative RCT</td>
<td>Marketed as medical food</td>
</tr>
<tr>
<td>Xaliproden</td>
<td>Sanofi-Aventis</td>
<td>Neuroprotection</td>
<td>AD</td>
<td>Preclinical data</td>
<td>Negative RCT</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>NIA</td>
<td>Antioxidant</td>
<td>Normal, MCI, AD</td>
<td>Positive AD trial</td>
<td>Negative MCI trial</td>
<td>Use limited by toxicity concerns</td>
</tr>
<tr>
<td>Ginkgo biloba</td>
<td>NIA, Schwabe, Ipsen</td>
<td>Antioxidant</td>
<td>Normal, AD</td>
<td>Some randomized trials in AD</td>
<td>Negative AD and prevention trials</td>
<td>Over-the-counter preparations widely used</td>
</tr>
<tr>
<td>Idebenone</td>
<td>Takeda</td>
<td>Antioxidant</td>
<td>AD</td>
<td>Preclinical data</td>
<td>Randomized trial</td>
<td>Not actively pursued for AD</td>
</tr>
<tr>
<td>Acetyl-l-carnitine</td>
<td>Sigma Tau</td>
<td>Antioxidant</td>
<td>AD</td>
<td>Preclinical data</td>
<td>Randomized trials</td>
<td>Two negative RCTs</td>
</tr>
<tr>
<td>Leuprolide</td>
<td>Curaxis</td>
<td>Gonadotropin pathways</td>
<td>AD</td>
<td>Preclinical studies, epidemiology</td>
<td>Randomized trial</td>
<td>Negative RCT</td>
</tr>
<tr>
<td>NGF gene delivery</td>
<td>NIA Ceregene</td>
<td>Neurotrophic</td>
<td>AD</td>
<td>Phase I open label study</td>
<td>Requires neurosurgical procedure</td>
<td>Phase II in progress</td>
</tr>
</tbody>
</table>
demonstrate significant benefit (Harrington et al. 2009; Gold et al. 2010), although post-hoc analysis in an early study suggested benefit in the APOE ε4 negative subgroup (Risner et al. 2006).

**Dimebon (Latrepirdine)**

The course of the dimebon development program includes a number of interesting lessons on the process of bringing new AD treatments forward (Doody 2009). Dimebon was initially identified by Russian scientists who screened compounds available for clinical use in that country for activity similar to that of the established AD treatments. They sought a single compound that would combine cholinesterase inhibition with NMDA antagonism. The lead compound to arise from this process was dimebon, a drug used as an antihistamine in Russia until the late 1980s. Following an 8-week open trial in 14 patients (Bachurin et al. 2001), dimebon was licensed by a US company, Medivation, and underwent a 6-month, placebo-controlled Phase II trial, conducted in Russia, in 183 individuals with mild to moderate AD, similar in design to standard trials used with cholinesterase inhibitors and memantine. The results were strikingly positive, with consistent favorable effects on both primary and secondary measures of cognition, function, and behavior (Doody et al. 2008). Further, a blinded extension of the trial to 12 months indicated that benefits of the drug in comparison to placebo appeared to increase with time. This trial suggested that dimebon might have benefits beyond the expectations for a combined cholinesterase inhibitor/NMDA antagonist, and indeed the very limited potency against those targets argued that dimebon must work by a novel mechanism. Activity in vitro against models of mitochondrial toxicity supported that dimebon may be a mitochondrial cytoprotectant. Thus, a drug identified using standard screens appeared to be highly effective based on an unexpected and novel mechanism.

An international Phase III trial was launched to replicate the Russian study findings but including nearly 600 patients, and several other studies were started to explore the efficacy of dimebon added onto donepezil treatment, and to evaluate efficacy in moderate to severe AD. However, the confirmatory study results showed no efficacy, with no apparent explanation for this inconsistency with the Russian Phase II trial. Another Phase III trial, assessing the addition of dimebon to standard therapy for 1 year, continues. Lessons from the dimebon program include the role of serendipity, and the unpredictability and inconsistency in Phase II and smaller sample size AD trials learned from other programs (Schneider 2008b), as well as reasons specific to this drug (Jones 2010).

**Statins**

Epidemiological evidence suggests that cholesterol lowering and the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (“statins”) may modulate the enzymatic processing of amyloid precursor protein and consequently the production of β-amyloid, and impact the development or progression of AD. Furthermore, cholesterol-fed rabbits show increased Aβ in brain, and hypercholesterolemia induced by a high-cholesterol diet results in increased levels of Aβ in the CNS. Statin administration in vitro reduces intra- and extracellular Aβ levels in neuronal cultures. Observational studies of patient records showed a 60–73% lower prevalence of and markedly reduced risk for AD in lovastatin (Mevacor)- or pravastatin (Pravachol)-treated patients.

Clinical trials, however, have not supported the use of statins for AD. A randomized, placebo-controlled trial of pravastatin in 5804 subjects with risk factors for vascular disease reported favorable cardiovascular outcomes but no significant effect on cognitive function or disability during an approximately 3-year follow-up period (Trompet et al. 2010). In a randomized, placebo-controlled trial of the effect of simvastatin on cardiovascular outcomes in a subgroup of 5806 patients aged 70 or more years, there was no significant difference in the proportion of patients with cognitive impairment or in the incidence of...
dementia over the average 5-year follow-up period. Two large placebo-controlled trials, one with simvastatin and another with atorvastatin, over 18 months did not show positive effects for the drugs in slowing the clinical decline (McGuinness et al. 2009).

Estrogens

Preclinical evidence amply demonstrates that estrogens improve cognitive function through cholinergic neuroprotective and neurotrophic effects. Clinical evidence of a possible effect for estrogen replacement therapy (ERT) has included observations of an inverse relationship between ERT and death-certificate diagnoses of dementia, several case-control and cohort studies in which hormonal therapy reducing the risk of AD were reported, and small clinical reports suggesting that estradiol, estrone, or conjugated equine estrogens enhance cognitive function in AD (Henderson 2006). However, larger studies have not confirmed benefits (Mulnard et al. 2000). Indeed, the large Women’s Health Initiative trial revealed an increased risk of dementia and cognitive impairment in women treated with hormone replacement therapy (Shumaker et al. 2003). It is possible but not proven that estrogen treatment in midlife around menopause could be neurotrophic and preventative of the onset of AD, but beyond a few epidemiological studies, evidence is lacking. Particularly in view of growing concerns about adverse health effects, the use of estrogen replacement late in life to prevent or treat MCI or AD cannot be recommended.

ANTI-INFLAMMATORY DRUGS

There has been enormous interest for more than two decades in the suppression of brain inflammatory activity as an approach to slowing disease progression in AD. Unfortunately, randomized trials of multiple anti-inflammatory regimens, including glucocorticoids (Aisen et al. 2000), nonsteroidal anti-inflammatory drugs (both nonselective and COX-2 selective) (Aisen et al. 2003; Lyketsos et al. 2007), hydroxychloroquine (Van Gool et al. 2001), and dapsone have all failed to demonstrate efficacy.

Curcumin is the active ingredient of curry spicy and is widely used as a food additive in Asian cooking. It has antioxidant properties and has been shown in experimental models to have anti-inflammatory, antioxidant, and anti-amyloid effects (Ringman et al. 2005). There is concern about the brain bioavailability of curcumin, however, and improved formulations are being sought.

INHIBITOR OF THE RECEPTOR FOR ADVANCED GLYcation ENDPRODUCTS

The receptor for advanced glycation endproducts (RAGE) is present on neurons, glia, and endothelial cells and is mainly of interest in diabetes and vascular disease in which there is an increased level of various ligands including advanced glycation endproducts that bind to it, effecting pro-inflammatory activity. It is of interest in AD because of a relationship of AD to diabetes and because the amyloid peptide is also a RAGE ligand, and this interaction may contribute to brain inflammation and accumulation of amyloid. The latter effect might result in increased CNS Aβ as well as inflammatory effects in AD patients. Thus RAGE blockers could be therapeutically useful in diabetes and AD. After a small Phase II trial indicated the tolerability of an oral inhibitor of RAGE in AD (Sabbagh et al. 2010), an 18-month trial was launched, with results expected soon.

NGF GENE DELIVERY

The most important component of the brain’s capacity to protect the function of cholinergic neurons is nerve growth factor (NGF). Early attempts to utilize NGF to protect these neurons in AD were unsuccessful because of toxicity; NGF delivered into the CSF stimulates ependymal cell proliferation with resulting toxicity such as pain. The advance of gene delivery methods has led to a resurgence of interest in NGF; primate studies showed that NGF gene delivery to the cholinergic nucleus basalis
resulted in long-term gene expression with neurotrophic effects.

A Phase I study of stereotactic NGF gene delivery using transformed fibroblasts derived from skin biopsies showed that NGF expression could be induced in nucleus basalis cells in humans with AD, with some evidence of increased brain function by FDG-PET scanning (Tuszynski et al. 2005). An NIA-funded, randomized, sham-surgery controlled Phase II trial of NGF gene delivery using a viral vector is currently in progress.

SIRTUINS AND RESVERATROL

Modifications of DNA and post-translational nuclear proteins may produce lasting alterations in chromatin, alter patterns of gene expression, and may affect neuroplasticity. Dysregulation of such epigenetic mechanisms may affect aging brain and cognitive impairment. Histone deacetylation (HDAC) may contribute to pathologic transcriptional aberrations in brain disease and HDAC activation may have therapeutic potential. Sirtuins, a family of histone deacetylation compounds, may be important to epigenetic mechanisms, and may be involved in the cellular protection afforded by calorie restriction (Gan 2007). Targeting sirtuins represents a new approach to neurodegenerative disorders.

There is great interest in the potential benefits of polyphenolic compounds derived from various fruits, vegetables, and plants. Polyphenols are potent antioxidants in vitro, and have been studied as potential therapeutics in cardiovascular disease and cancer, in part based on epidemiological evidence. Similarly, there is interest in polyphenols to reduce the adverse effects of aging on the function of organs including brain; neuroprotective effects have been shown in vitro.

Resveratrol is a polyphenol particularly abundant in the skin of red grapes; it has been suggested that this may in part explain epidemiological links between red wine consumption and reduced risk of AD (Vingtdeux et al. 2008). In vivo data have clearly shown the neuroprotective properties of the naturally occurring polyphenol resveratrol in rodent models for stress and diseases. Furthermore, recent work in cell cultures and animal models has shed light on the molecular mechanisms potentially involved in the beneficial effects of resveratrol intake against the neurodegenerative process in AD. Laboratory studies indicate that resveratrol is an activator of sirtuins. Resveratrol and other sirtuin activators increase longevity and slow brain atrophy in a number of species including nonhuman primates.

Although brain penetration of resveratrol is limited, some studies suggest that it may have a peripheral action that reduces brain amyloid accumulation. A NIA-funded study of the impact of resveratrol on biomarkers of AD will be initiated in early 2011.

SUMMARY

AChE-Is and the NMDA receptor antagonist memantine are FDA approved for treatment of AD. Transmitter based therapies represent the only validated treatments of AD. Deficits in transmitters not addressed by current therapies suggest that manipulation of these transmitter systems are worthy targets for cognitive enhancement. A plethora of metabolic, intracellular, and neuroprotective approaches populate this potential therapeutic space and represent new and emerging treatments for AD. Particularly for drug development programs aiming to slow progression of underlying pathobiological mechanisms, clinical impact is likely to be greatest if treatment is initiated early, prior to the onset of dementia or even in the presymptomatic stage of the disease process.

ACKNOWLEDGMENTS

Dr. Aisen serves on a scientific advisory board for NeuroPhage and serves as a consultant to Elan Corporation, Wyeth, Eisai Inc., Schering-Plough Corp., Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck & Co., Roche, Amgen, Genentech, Inc., Abbott, Pfizer Inc, Novartis, Bayer, and Medivation, Inc. He receives research support from Pfizer Inc, Baxter International Inc., and the NIH [NIA
P.S. Aisen et al.

U01-AG10483 (PI), NIA U01-AG024904 (Coordinating Center Director), NIA R01-AG030048 (PI), and R01-AG16381 (Co-I); and he has received stock options from Medivation, Inc. and NeuroPhage.

Dr. Cummings has provided consultation to Abbott, Acadia, ADAMAS, Astellas, Baxter, Bayer, Bristol-Meyers Squibb, Eisai, EnVivo, Forest, Genentech, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Merck, Neurokos, Novartis, Pfizer, Prana, QR Pharma, reMYND, Signum, Sonexa, Takeda, and Toyama pharmaceutical companies. He has stock options in ADAMAS, Prana, Sonexa, and Neurokos. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.

Dr. Schneider reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia. He received a grant from the Alzheimer’s Association for a registry for dementia and cognitive impairment trials; he is also in receipt of grant or research support from Baxter, Elan Pharmaceuticals, Johnson & Johnson, Eli Lilly, Myriad, Novartis, and Pfizer. He has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Eli, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Schwabe, Toyama, and Transition Therapeutics.

REFERENCES


Symptomatic and Other Treatments for Alzheimer Disease


Cite this article as: *Cold Spring Harb Perspect Med* 2012;2:a006395
P.S. Aisen et al.


Symptomatic and Other Treatments for Alzheimer Disease


Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

Paul S. Aisen, Jeffrey Cummings and Lon S. Schneider

Cold Spring Harb Perspect Med 2012; doi: 10.1101/cshperspect.a006395 originally published online November 30, 2011

Subject Collection  The Biology of Alzheimer Disease

Animal Models of Alzheimer Disease  
Frank M. LaFerla and Kim N. Green

Neurovascular Dysfunction and Faulty Amyloid β-Peptide Clearance in Alzheimer Disease  
Abhay P. Sagare, Robert D. Bell and Berislav V. Zlokovic

Treatment Strategies Targeting Amyloid β-Protein  
Dale Schenk, Guriqbal S. Basi and Menelas N. Pangalos

The Ubiquitin–Proteasome System and the Autophagic–Lysosomal System in Alzheimer Disease  
Yasuo Ihara, Maho Morishima-Kawashima and Ralph Nixon

Neurotoxicity of Amyloid β-Protein: Synaptic and Network Dysfunction  
Lennart Mucke and Dennis J. Selkoe

Proteolytic Degradation of Amyloid β-Protein  
Takaomi Saido and Malcolm A. Leissring

Brain Imaging in Alzheimer Disease  
Keith A. Johnson, Nick C. Fox, Reisa A. Sperling, et al.

Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease  
Paul S. Aisen, Jeffrey Cummings and Lon S. Schneider

Alzheimer Disease in 2020  
David M. Holtzman, Eckhard Mandelkow and Dennis J. Selkoe

The Genetics of Alzheimer Disease  
Rudolph E. Tanzi

Fluid Biomarkers in Alzheimer Disease  
Kaj Blennow, Henrik Zetterberg and Anne M. Fagan

Epidemiology of Alzheimer Disease  
Richard Mayeux and Yaakov Stern

Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration  
Eva-Maria Mandelkow and Eckhard Mandelkow

Biochemistry of Amyloid β-Protein and Amyloid Deposits in Alzheimer Disease  
Colin L. Masters and Dennis J. Selkoe

The Neuropsychological Profile of Alzheimer Disease  
Sandra Weintraub, Alissa H. Wicklund and David P. Salmon

Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease  
David M. Hölzman, Joachim Herz and Guojun Bu

For additional articles in this collection, see http://perspectivesinmedicine.cshlp.org/cgi/collection/

Copyright © 2012 Cold Spring Harbor Laboratory Press; all rights reserved